MOPA — Medical Oncology Prior Authorization - Local Development build (v0.1.1-snapshot-080926) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions
| Official URL: http://hl7.org/fhir/us/codex-mopa/ValueSet/treatment-line-vs | Version: 0.1.1-snapshot-080926 | ||||
| Standards status: Informative | Computable Name: TreatmentLineVS | ||||
Codes representing the ordinal line of systemic anti-cancer therapy. Used by LineOfTherapyRequestCategory for the patient-specific RequestGroup category.
mCODE Migration Candidate — Proposed for mCODE STU5.
References
⚠ mCODE Migration Candidate
This Treatment Line Value Set is defined in this IG as a temporary home while a formal proposal to incorporate it into mCODE STU5 is developed. It is not intended to be a permanent artifact of the MOPA IG. Once adopted by mCODE, this IG will remove its local definition and reference the mCODE canonical URL instead.
This artifact carries status = draft and experimental = true. Canonical URLs will change at
migration. See the mCODE Gap Proposals page for the full proposal backlog.
http://hl7.org/fhir/us/codex-mopa/CodeSystem/treatment-line-cs version 📦0.1.1-snapshot-080926
Expansion performed internally based on codesystem Treatment Line Code System v0.1.1-snapshot-080926 (CodeSystem)
This value set contains 4 concepts
| System | Code | Display (en) | Definition | JSON | XML |
http://hl7.org/fhir/us/codex-mopa/CodeSystem/treatment-line-cs | 1L | First-line | The first line of systemic anti-cancer therapy for this indication. | ||
http://hl7.org/fhir/us/codex-mopa/CodeSystem/treatment-line-cs | 2L | Second-line | The second line of systemic anti-cancer therapy; administered after first-line therapy failure, progression, or intolerance. | ||
http://hl7.org/fhir/us/codex-mopa/CodeSystem/treatment-line-cs | 3L-plus | Third-line or later | The third or any subsequent line of systemic anti-cancer therapy. | ||
http://hl7.org/fhir/us/codex-mopa/CodeSystem/treatment-line-cs | maintenance | Maintenance | Maintenance therapy administered to prolong response after induction or consolidation treatment. |